than zolmitriptan, is metabolized into an inactive form by monoamine oxidase A (MAO-A). The reversible inhibitor of MAO-A (RIMA) moclobemide combined with zolmitriptan has been found to increase N-desmethylzolmitriptan exposure and peak levels by 1.5- to 3-fold.

Pharmacology

Pharmacodynamics

Zolmitriptan is a selective